Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 21 | 2021 | 424 | 2.440 |
Why?
|
| Homosexuality, Male | 7 | 2021 | 105 | 1.180 |
Why?
|
| Anti-HIV Agents | 6 | 2017 | 61 | 1.100 |
Why?
|
| Bisexuality | 3 | 2021 | 32 | 0.750 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 72 | 0.590 |
Why?
|
| Viral Load | 6 | 2018 | 73 | 0.540 |
Why?
|
| North Carolina | 14 | 2021 | 1546 | 0.540 |
Why?
|
| Rural Population | 4 | 2015 | 286 | 0.520 |
Why?
|
| Community-Based Participatory Research | 5 | 2021 | 120 | 0.520 |
Why?
|
| HIV-1 | 3 | 2015 | 45 | 0.480 |
Why?
|
| Internet | 4 | 2011 | 201 | 0.430 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2017 | 29 | 0.410 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2012 | 37 | 0.380 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2011 | 1 | 0.360 |
Why?
|
| Nitriles | 1 | 2011 | 23 | 0.360 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 16 | 0.350 |
Why?
|
| Adult | 22 | 2021 | 9569 | 0.350 |
Why?
|
| Pyrimidines | 1 | 2011 | 62 | 0.340 |
Why?
|
| Qualitative Research | 4 | 2021 | 199 | 0.320 |
Why?
|
| Appointments and Schedules | 3 | 2019 | 22 | 0.310 |
Why?
|
| Health Education | 2 | 2010 | 162 | 0.310 |
Why?
|
| HIV | 2 | 2019 | 25 | 0.310 |
Why?
|
| Humans | 29 | 2021 | 32814 | 0.280 |
Why?
|
| Male | 25 | 2021 | 19650 | 0.280 |
Why?
|
| Hispanic Americans | 4 | 2021 | 930 | 0.270 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 22 | 0.260 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2017 | 32 | 0.260 |
Why?
|
| Referral and Consultation | 2 | 2019 | 147 | 0.260 |
Why?
|
| Young Adult | 11 | 2019 | 2734 | 0.250 |
Why?
|
| Ambulatory Care Facilities | 3 | 2019 | 83 | 0.190 |
Why?
|
| HIV Seropositivity | 2 | 2014 | 14 | 0.190 |
Why?
|
| Emigrants and Immigrants | 4 | 2012 | 240 | 0.180 |
Why?
|
| Interviews as Topic | 2 | 2021 | 272 | 0.180 |
Why?
|
| Health Services Accessibility | 2 | 2015 | 252 | 0.180 |
Why?
|
| Middle Aged | 16 | 2019 | 12133 | 0.180 |
Why?
|
| Female | 17 | 2019 | 20271 | 0.170 |
Why?
|
| Patient Dropouts | 2 | 2019 | 25 | 0.160 |
Why?
|
| Medication Adherence | 2 | 2012 | 160 | 0.160 |
Why?
|
| African Continental Ancestry Group | 1 | 2021 | 363 | 0.150 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 289 | 0.150 |
Why?
|
| Directive Counseling | 1 | 2019 | 17 | 0.150 |
Why?
|
| Case Management | 1 | 2018 | 5 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2019 | 109 | 0.140 |
Why?
|
| Strongyloidiasis | 1 | 2017 | 3 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 19 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2015 | 3441 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 360 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 271 | 0.130 |
Why?
|
| Smoking Cessation | 1 | 2019 | 216 | 0.130 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2017 | 9 | 0.130 |
Why?
|
| European Continental Ancestry Group | 1 | 2021 | 1163 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2017 | 51 | 0.120 |
Why?
|
| Social Support | 2 | 2019 | 183 | 0.120 |
Why?
|
| Smoking | 1 | 2019 | 531 | 0.120 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2015 | 7 | 0.120 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2015 | 2 | 0.120 |
Why?
|
| Pyridazines | 1 | 2015 | 7 | 0.120 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 779 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 105 | 0.110 |
Why?
|
| Southeastern United States | 5 | 2014 | 79 | 0.110 |
Why?
|
| Risk-Taking | 3 | 2011 | 96 | 0.110 |
Why?
|
| Bone Density | 1 | 2015 | 203 | 0.100 |
Why?
|
| Pruritus | 1 | 2014 | 47 | 0.100 |
Why?
|
| Adolescent | 7 | 2019 | 3640 | 0.100 |
Why?
|
| Sexual Behavior | 2 | 2012 | 125 | 0.100 |
Why?
|
| Diffusion of Innovation | 1 | 2012 | 34 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 84 | 0.090 |
Why?
|
| Mexican Americans | 1 | 2012 | 60 | 0.090 |
Why?
|
| Aged | 5 | 2014 | 10544 | 0.090 |
Why?
|
| Pharmaceutical Preparations | 1 | 2011 | 37 | 0.090 |
Why?
|
| Safe Sex | 2 | 2009 | 14 | 0.090 |
Why?
|
| AIDS Serodiagnosis | 1 | 2011 | 4 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2015 | 1844 | 0.090 |
Why?
|
| Commerce | 1 | 2011 | 69 | 0.080 |
Why?
|
| Sexual Partners | 2 | 2009 | 36 | 0.080 |
Why?
|
| Intention | 1 | 2011 | 32 | 0.080 |
Why?
|
| Peer Group | 2 | 2010 | 45 | 0.080 |
Why?
|
| Time Factors | 2 | 2015 | 2183 | 0.080 |
Why?
|
| Community-Institutional Relations | 2 | 2007 | 19 | 0.080 |
Why?
|
| RNA, Viral | 1 | 2009 | 49 | 0.080 |
Why?
|
| Focus Groups | 2 | 2007 | 128 | 0.080 |
Why?
|
| Heterosexuality | 1 | 2009 | 15 | 0.070 |
Why?
|
| African Americans | 1 | 2015 | 1424 | 0.070 |
Why?
|
| Quality of Life | 1 | 2014 | 962 | 0.070 |
Why?
|
| Ritonavir | 1 | 2007 | 3 | 0.070 |
Why?
|
| Pyrimidinones | 1 | 2007 | 4 | 0.070 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2007 | 4 | 0.070 |
Why?
|
| Condoms | 1 | 2007 | 34 | 0.070 |
Why?
|
| Methamphetamine | 1 | 2007 | 19 | 0.070 |
Why?
|
| Drug Resistance, Viral | 3 | 2015 | 9 | 0.070 |
Why?
|
| Morbidity | 1 | 2007 | 101 | 0.070 |
Why?
|
| Health Behavior | 1 | 2009 | 234 | 0.070 |
Why?
|
| Unsafe Sex | 1 | 2007 | 23 | 0.060 |
Why?
|
| Poverty | 1 | 2007 | 116 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2285 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2007 | 218 | 0.060 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 29 | 0.060 |
Why?
|
| Community Health Services | 1 | 2006 | 58 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2007 | 163 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 894 | 0.060 |
Why?
|
| Age Factors | 1 | 2007 | 1197 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2017 | 288 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 4034 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 98 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 2012 | 131 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2011 | 565 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 181 | 0.030 |
Why?
|
| Telephone | 1 | 2018 | 58 | 0.030 |
Why?
|
| Strongyloides stercoralis | 1 | 2017 | 3 | 0.030 |
Why?
|
| Piperacillin | 1 | 2017 | 6 | 0.030 |
Why?
|
| Penicillanic Acid | 1 | 2017 | 6 | 0.030 |
Why?
|
| Antiparasitic Agents | 1 | 2017 | 6 | 0.030 |
Why?
|
| Ivermectin | 1 | 2017 | 9 | 0.030 |
Why?
|
| Klebsiella pneumoniae | 1 | 2017 | 14 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 82 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 51 | 0.030 |
Why?
|
| Patient Participation | 1 | 2018 | 87 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2014 | 1461 | 0.030 |
Why?
|
| Bacteremia | 1 | 2017 | 65 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 72 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2017 | 17 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2017 | 32 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1572 | 0.030 |
Why?
|
| Mass Screening | 1 | 2019 | 268 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 682 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 156 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 332 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 764 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 126 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 185 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 201 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2012 | 6 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 410 | 0.020 |
Why?
|
| Reproductive Health Services | 1 | 2012 | 5 | 0.020 |
Why?
|
| Consumer Health Information | 1 | 2011 | 15 | 0.020 |
Why?
|
| Risk Factors | 2 | 2012 | 3976 | 0.020 |
Why?
|
| Cultural Competency | 1 | 2011 | 17 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 110 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1002 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 881 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 436 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 783 | 0.020 |
Why?
|
| United States | 1 | 2019 | 4109 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 125 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 229 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2007 | 1 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 731 | 0.020 |
Why?
|
| Videotape Recording | 1 | 2007 | 13 | 0.020 |
Why?
|
| Stereotyping | 1 | 2007 | 10 | 0.020 |
Why?
|
| Narration | 1 | 2007 | 18 | 0.020 |
Why?
|
| Students | 1 | 2009 | 179 | 0.020 |
Why?
|
| Prejudice | 1 | 2007 | 49 | 0.020 |
Why?
|
| Mutation | 1 | 2009 | 493 | 0.020 |
Why?
|
| Spirituality | 1 | 2007 | 37 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 185 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 128 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 7570 | 0.020 |
Why?
|
| Health Promotion | 1 | 2007 | 255 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2006 | 197 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 3705 | 0.010 |
Why?
|